Tvardi Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing innovative oral small molecule therapies targeting the STAT3 protein, which plays a crucial role in various signaling pathways associated with cancer, chronic inflammation, and fibrosis. Their lead product, TTI-101, is a direct inhibitor of STAT3 that has shown promise in preclinical studies and is currently being evaluated in clinical trials for its efficacy in treating advanced solid tumors and idiopathic pulmonary fibrosis (IPF). The company aims to address significant unmet medical needs in fibrosis-driven diseases, leveraging the therapeutic potential of STAT3 inhibition to reverse fibrotic conditions and restore normal organ function.

The scientific foundation of Tvardi's approach lies in the understanding that STAT3 is a key regulatory protein involved in the survival and immune evasion of cancer cells, as well as in the pathogenesis of inflammatory and fibrotic diseases. By inhibiting STAT3 signaling, Tvardi's therapies are expected to exert synergistic effects on cancer cells while also mitigating chronic inflammation and fibrosis. The ongoing clinical trials for TTI-101 are designed to assess its safety and efficacy across various conditions, including advanced cancers and IPF, highlighting the company's commitment to advancing breakthrough medicines for patients with critical health challenges.

United States

Tvardi Therapeutics is a private, clinical stage biotechnology company developing medicines for diverse cancers and chronic inflammatory and fibrotic diseases. Tvardi is focused on the development of orally delivered, small molecule inhibitors of STAT3, a key signaling molecule positioned at the intersection of many disease pathways.

Tvardi Therapeutics

Company Details